![](https://www.molecular-medicine-israel.co.il/wp-content/uploads/2017/11/prostate-cancer-dreamstime-300x150.jpg)
The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer
Abstract Aberrant activation of Ras/Raf/mitogen-activated protein kinase (MAPK) signaling is frequently linked to metastatic prostate cancer (PCa); therefore, the characterization of modulators of this pathway